Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerBiologics

PUBLISHER: Grand View Research | PRODUCT CODE: 1908695

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1908695

Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Immunomodulators), By Application, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Cancer Immunotherapy Market Summary

The global cancer immunotherapy market size was estimated at USD 153.27 billion in 2025 and is projected to reach USD 305.80 billion by 2033, growing at a CAGR of 9.02% from 2026 to 2033. The increasing prevalence of cancer is a significant factor driving market growth.

According to the American Cancer Society Journal, in the U.S., about 2 million new cancer cases and 611,720 cancer deaths are estimated to occur in the year 2024. Growing R&D activities by pharmaceutical companies, technological advancements, and the introduction of novel drugs are expected to drive the growth of the cancer immunotherapy industry in the forecast period. The increasing prevalence of cancer is boosting the demand for the cancer immunotherapy market. According to the International Agency for Research on Cancer (IARC) estimates, in the year 2020, there were about 19.29 million cancer cases, which is estimated to increase to 24.58 million cases by 2030. This significant increase in the disease burden on the population is expected to drive the market growth.

Rising approval of novel immunotherapies is expected to propel the market growth over the forecast period. For instance, in December 2024, AstraZeneca's immunotherapy drug Imfinzi (durvalumab) became the first and only approved regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy. Similarly, the increasing patient preference for subcutaneous drug administration is fueling market growth. In September 2024, the FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor, representing a significant breakthrough in cancer immunotherapy. This formulation offers patients a faster treatment option (7 minutes versus 30-60 minutes for intravenous infusion) while maintaining the same safety and efficacy as the intravenous version.

Various strategic initiatives undertaken by major players are also anticipated to facilitate the market demand. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop the Oncology Therapeutics. The collaboration includes an assessment of Immatics' investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. These aspects are driving the market growth.

Global Cancer Immunotherapy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer immunotherapy market report based on product, application, distribution channel, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Immunomodulators
  • Oncolytic Viral Therapies and Cancer Vaccines
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and Neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Clinics
  • Cancer Research Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-1-68038-693-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. Distribution
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Growing R&D activities by pharmaceutical companies
      • 3.2.1.3. Technological advancements and introduction of novel drugs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of side effects associated with the treatment
      • 3.2.2.2. High cost of therapy and unfavourable reimbursement scenario
  • 3.3. Cancer Immunotherapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2025 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Cancer Immunotherapy Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Monoclonal Antibodies
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Immunomodulators
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2025 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Cancer Immunotherapy Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Lung Cancer
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Breast Cancer
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Colorectal Cancer
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Melanoma
      • 5.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Prostate Cancer
      • 5.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. Head and Neck Cancer
      • 5.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.7. Ovarian Cancer
      • 5.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.8. Pancreatic Cancer
      • 5.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis

  • 6.1. Distribution Market Share, 2025 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Cancer Immunotherapy Market by Distribution Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Hospital Pharmacy
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Retail Pharmacy
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Online Pharmacy
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis

  • 7.1. Distribution Market Share, 2025 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Cancer Immunotherapy Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 7.4.1. Hospitals & Clinics
      • 7.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 7.4.2. Cancer Research Centers
      • 7.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Pfizer Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. AstraZeneca
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Merck & Co., Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. F. Hoffmann-La Roche Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Bristol-Myers Squibb Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Novartis AG
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Lilly
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Immunocore, Ltd
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
Show more
Product Code: GVR-1-68038-693-6

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 4 North America Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 5 North America Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 6 North America Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S. Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 8 U.S. Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 9 U.S. Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 10 U.S. Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 12 Canada Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 13 Canada Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 16 Mexico Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Germany Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 25 Germany Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 26 Germany Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 28 UK Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 29 UK Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 30 UK Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 31 UK Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 32 France Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 33 France Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 34 France Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 35 France Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 36 Italy Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 37 Italy Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 38 Italy Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 39 Italy Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Spain Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 41 Spain Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 42 Spain Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 43 Spain Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Denmark Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 45 Denmark Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 48 Sweden Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 49 Sweden Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 50 Sweden Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 51 Sweden Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 52 Norway Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 53 Norway Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 54 Norway Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 55 Norway Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 59 Asia Pacific Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 61 China Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 62 China Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 63 China Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 64 China Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 65 Japan Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 66 Japan Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 67 Japan Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 68 Japan Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 69 India Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 70 India Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 71 India Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 72 India Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 73 South Korea Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 74 South Korea Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 75 South Korea Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 76 South Korea Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 77 Australia Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 78 Australia Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 79 Australia Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 80 Australia Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 81 Thailand Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 82 Thailand Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 83 Thailand Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 84 Thailand Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Latin America Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 86 Latin America Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 87 Latin America Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 88 Latin America Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 89 Latin America Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Brazil Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 91 Brazil Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 92 Brazil Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 93 Brazil Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 94 Argentina Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 95 Argentina Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 96 Argentina Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 97 Argentina Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 98 MEA Cancer Immunotherapy market, by region, 2021 - 2033 (USD Million)
  • Table 99 MEA Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 100 MEA Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 101 MEA Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 102 MEA Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 103 South Africa Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 104 South Africa Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 105 South Africa Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 106 South Africa Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 111 UAE Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 112 UAE Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 113 UAE Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 114 UAE Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)
  • Table 115 Kuwait Cancer Immunotherapy market, by product, 2021 - 2033 (USD Million)
  • Table 116 Kuwait Cancer Immunotherapy market, by application, 2021 - 2033 (USD Million)
  • Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2021 - 2033 (USD Million)
  • Table 118 Kuwait Cancer Immunotherapy market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Cancer Immunotherapy market: market outlook
  • Fig. 14 Cancer Immunotherapy competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Cancer Immunotherapy market driver impact
  • Fig. 20 Cancer Immunotherapy market restraint impact
  • Fig. 21 Cancer Immunotherapy market strategic initiatives analysis
  • Fig. 22 Cancer Immunotherapy market: Product movement analysis
  • Fig. 23 Cancer Immunotherapy market: Product outlook and key takeaways
  • Fig. 24 Monoclonal Antibodies market estimates and forecast, 2021 - 2033
  • Fig. 25 Immunomodulators market estimates and forecast, 2021 - 2033
  • Fig. 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2021 - 2033
  • Fig. 27 Cancer Immunotherapy Market: Application movement analysis
  • Fig. 28 Cancer Immunotherapy market: Application outlook and key takeaways
  • Fig. 29 Lung Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 30 Breast Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 31 Colorectal Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 32 Melanoma market estimates and forecasts, 2021 - 2033
  • Fig. 33 Prostate Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 34 Head and Neck Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 35 Ovarian Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 36 Pancreatic Cancer market estimates and forecasts, 2021 - 2033
  • Fig. 37 Others market estimates and forecasts, 2021 - 2033
  • Fig. 38 Cancer Immunotherapy market: Distribution movement analysis
  • Fig. 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
  • Fig. 40 Hospital Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 41 Retail Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 42 Online Pharmacy market estimates and forecasts, 2021 - 2033
  • Fig. 43 Cancer Immunotherapy market: End Use movement analysis
  • Fig. 44 Cancer Immunotherapy market: End Use outlook and key takeaways
  • Fig. 45 Hospitals & Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 46 Cancer Research Centers market estimates and forecasts, 2021 - 2033
  • Fig. 47 Others market estimates and forecasts, 2021 - 2033
  • Fig. 48 Global Cancer Immunotherapy market: Regional movement analysis
  • Fig. 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
  • Fig. 50 Global Cancer Immunotherapy market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America, by country
  • Fig. 62 North America
  • Fig. 63 North America market estimates and forecasts, 2021 - 2033
  • Fig. 64 U.S.
  • Fig. 65 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 66 Canada
  • Fig. 67 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 72 UK
  • Fig. 73 UK market estimates and forecasts, 2021 - 2033
  • Fig. 74 Germany
  • Fig. 75 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 76 France
  • Fig. 77 France market estimates and forecasts, 2021 - 2033
  • Fig. 78 Italy
  • Fig. 79 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 80 Spain
  • Fig. 81 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 82 Denmark
  • Fig. 83 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 84 Sweden
  • Fig. 85 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 86 Norway
  • Fig. 87 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 90 China
  • Fig. 91 China market estimates and forecasts, 2021 - 2033
  • Fig. 92 Japan
  • Fig. 93 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 94 India
  • Fig. 95 India market estimates and forecasts, 2021 - 2033
  • Fig. 96 Thailand
  • Fig. 97 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 98 South Korea
  • Fig. 99 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 100 Australia
  • Fig. 101 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 104 Brazil
  • Fig. 105 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 106 Argentina
  • Fig. 107 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 108 Middle East and Africa
  • Fig. 109 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 110 South Africa
  • Fig. 111 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 112 Saudi Arabia
  • Fig. 113 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 114 UAE
  • Fig. 115 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 116 Kuwait
  • Fig. 117 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 118 Market share of key market players- Cancer Immunotherapy market
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!